Guidance Update

Alico's Q3 results reveal a successful pivot from citrus giant to land developer, with profits soaring and major projects advancing. How is this changing Florida?

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.

AGCO's stock plunged after a surprise guidance cut, triggering a legal probe. We dissect if this was just a market downturn or a failure in transparency.

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

Dauch Corporation's sales nearly double after its massive Dowlais acquisition, but GAAP profits vanish. A deep dive reveals a complex integration story.

Beyond a massive tariff refund that doubled profits, Spectrum Brands' Q3 reveals solid growth in its core, a record quarter in Home & Garden, and a key tech upgrade.

Despite a revenue dip, Embecta's stock soared after crushing Q3 profit estimates, signaling its strategic pivot beyond insulin is starting to pay off.

Amidst declining North American sales, Under Armour is cutting products and chasing a premium identity. But can cost cuts and tariff refunds fuel a real comeback?

Interface posted stellar Q2 results, but a one-time $15.6M tariff refund inflated the numbers. The real story is the operational resilience of its strategy.

While others wait for the housing market to recover, James Hardie is building its own boom. A deep dive into the strategic execution driving its success.

Beyond strong Q2 earnings, a forensic look at CBL's strategy reveals how aggressive debt restructuring and portfolio reinvention are creating a new model for retail.

With record revenues and a raised outlook, Ryman Hospitality's Q2 results reveal more than just strong bookings—they map the future of group travel.

Starling Oncology just hit positive Adjusted EBITDA, a milestone for its value-based care model. Is this the inflection point for profitability in oncology?

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

Despite a net loss, Drilling Tools International's Q2 results show surprising strength, driven by innovative tech and robust free cash flow.

The luxury resale giant posted a record quarter and raised its 2026 forecast, but a wider GAAP loss tells a more complex story of strategic growth.

Genpact's stellar Q2 results are more than just numbers; they're proof of a strategic pivot to 'Agentic Operations' that could reshape the BPO landscape.

A stunning quarter for Establishment Labs shows a company moving from high-growth potential to high-growth reality, underpinned by strategic discipline.